Company registration number 03802833 (England and Wales)
LANSDALES PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
PAGES FOR FILING WITH REGISTRAR
LANSDALES PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
LANSDALES PHARMACY LIMITED
BALANCE SHEET
AS AT
31 AUGUST 2025
31 August 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
1,923,565
2,071,107
Tangible assets
4
1,781,466
467,251
3,705,031
2,538,358
Current assets
Stocks
438,466
345,143
Debtors
5
1,591,363
1,299,839
Cash at bank and in hand
680,130
1,672,084
2,709,959
3,317,066
Creditors: amounts falling due within one year
6
(2,229,472)
(1,868,335)
Net current assets
480,487
1,448,731
Total assets less current liabilities
4,185,518
3,987,089
Creditors: amounts falling due after more than one year
7
(1,767,115)
(1,909,458)
Provisions for liabilities
(129,686)
(111,106)
Net assets
2,288,717
1,966,525
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
2,288,617
1,966,425
Total equity
2,288,717
1,966,525
LANSDALES PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 AUGUST 2025
31 August 2025
- 2 -

For the financial year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 28 April 2026 and are signed on its behalf by:
Mr KA Khaliq
Director
Company registration number 03802833 (England and Wales)
LANSDALES PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
- 3 -
1
Accounting policies
Company information

Lansdales Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is Lansdales Pharmacy, 17 Desborough Avenue, High Wycombe, Buckinghamshire, HP11 2RS.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover represents revenue generated from the pharmacy and is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

LANSDALES PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
No depreciation
Leasehold land and buildings
25% on cost
Fixtures and fittings
25% on reducing balance
Computers
25% on reducing balance
Motor vehicles
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

LANSDALES PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 5 -
1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
49
44
3
Intangible fixed assets
Goodwill
£
Cost
At 1 September 2024 and 31 August 2025
3,501,834
Amortisation and impairment
At 1 September 2024
1,430,727
Amortisation charged for the year
147,542
At 31 August 2025
1,578,269
Carrying amount
At 31 August 2025
1,923,565
At 31 August 2024
2,071,107
LANSDALES PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 6 -
4
Tangible fixed assets
Freehold land and buildings
Leasehold land and buildings
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 September 2024
-
0
255,617
1,143,294
210,910
236,097
1,845,918
Additions
1,254,559
-
0
240,700
-
0
11,320
1,506,579
At 31 August 2025
1,254,559
255,617
1,383,994
210,910
247,417
3,352,497
Depreciation and impairment
At 1 September 2024
-
0
251,682
821,081
170,780
135,124
1,378,667
Depreciation charged in the year
12,546
984
140,729
10,032
28,073
192,364
At 31 August 2025
12,546
252,666
961,810
180,812
163,197
1,571,031
Carrying amount
At 31 August 2025
1,242,013
2,951
422,184
30,098
84,220
1,781,466
At 31 August 2024
-
0
3,935
322,213
40,130
100,973
467,251
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
581,351
616,127
Other debtors
1,010,012
683,712
1,591,363
1,299,839
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
119,115
92,476
Trade creditors
1,245,830
967,173
Taxation and social security
190,765
193,615
Other creditors
673,762
615,071
2,229,472
1,868,335
LANSDALES PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 7 -
7
Creditors: amounts falling due after more than one year
2025
2024
Notes
£
£
Bank loans and overdrafts
1,767,115
1,909,458
Creditors which fall due after five years are payable as follows:
Payable by instalments
1,297,479
1,539,556

The bank loans are secured by way of a fixed and floating charge and a debenture over the assets of the Company.

8
Related party transactions
Remuneration of key management personnel

During the year, the company paid rent of £40,800 (2024:- £40,800) to Mr KA Khaliq for occupation of property of which he is the landlord.

Transactions with related parties

During the year the company entered into the following transactions with related parties:

The following amounts were outstanding at the reporting end date:

2025
2024
Amounts due from related parties
£
£
Entities with common controlling shareholders and directors
577,216
575,092

The above disclosed amount, which is included under other debtors, remained outstanding as of the balance sheet date. The loan is unsecured, interest free, and repayable on demand.

9
Directors' transactions

During the year, the company paid rent of £40,800 (2024:- £40,800) to Mr KA Khaliq for occupation of property of which he is the landlord.

2025-08-312024-09-01falsefalsefalse28 April 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr KA KhaliqMiss SH Khaliq038028332024-09-012025-08-31038028332025-08-31038028332024-08-3103802833core:NetGoodwill2025-08-3103802833core:NetGoodwill2024-08-3103802833core:LandBuildingscore:OwnedOrFreeholdAssets2025-08-3103802833core:FurnitureFittings2025-08-3103802833core:ComputerEquipment2025-08-3103802833core:MotorVehicles2025-08-3103802833core:LandBuildingscore:OwnedOrFreeholdAssets2024-08-3103802833core:LandBuildings2024-08-3103802833core:FurnitureFittings2024-08-3103802833core:ComputerEquipment2024-08-3103802833core:MotorVehicles2024-08-3103802833core:CurrentFinancialInstrumentscore:WithinOneYear2025-08-3103802833core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-3103802833core:WithinOneYear2025-08-3103802833core:WithinOneYear2024-08-3103802833core:AfterOneYear2025-08-3103802833core:AfterOneYear2024-08-3103802833core:CurrentFinancialInstruments2025-08-3103802833core:CurrentFinancialInstruments2024-08-3103802833core:ShareCapital2025-08-3103802833core:ShareCapital2024-08-3103802833core:RetainedEarningsAccumulatedLosses2025-08-3103802833core:RetainedEarningsAccumulatedLosses2024-08-3103802833bus:Director12024-09-012025-08-3103802833core:Goodwill2024-09-012025-08-3103802833core:LandBuildingscore:OwnedOrFreeholdAssets2024-09-012025-08-3103802833core:LandBuildingscore:LongLeaseholdAssets2024-09-012025-08-3103802833core:FurnitureFittings2024-09-012025-08-3103802833core:ComputerEquipment2024-09-012025-08-3103802833core:MotorVehicles2024-09-012025-08-31038028332023-09-012024-08-3103802833core:NetGoodwill2024-08-3103802833core:NetGoodwill2024-09-012025-08-3103802833core:LandBuildingscore:OwnedOrFreeholdAssets2024-08-3103802833core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-08-3103802833core:FurnitureFittings2024-08-3103802833core:ComputerEquipment2024-08-3103802833core:MotorVehicles2024-08-31038028332024-08-3103802833core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-08-3103802833core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-09-012025-08-3103802833core:Non-currentFinancialInstruments2025-08-3103802833core:Non-currentFinancialInstruments2024-08-3103802833bus:PrivateLimitedCompanyLtd2024-09-012025-08-3103802833bus:SmallCompaniesRegimeForAccounts2024-09-012025-08-3103802833bus:FRS1022024-09-012025-08-3103802833bus:AuditExemptWithAccountantsReport2024-09-012025-08-3103802833bus:Director22024-09-012025-08-3103802833bus:FullAccounts2024-09-012025-08-31xbrli:purexbrli:sharesiso4217:GBP